The Puerto Rican Association for Assistance to Psoriasis Patients (APAPP) announced the beginning of the first exploratory study on the psoriasis in Puerto Rico in order to deepen the understanding of this chronic autoimmune disease that affects thousands of people on the island, and for which there is no database, as well as to document the needs of patients and access to treatments.
“In the absence of a database of psoriasis patients in Puerto Rico, our organization has undertaken the task of conducting this study. with the main objective of collecting information that allows us to create a demographic profile of the psoriasis patient, to understand their knowledge and course of the disease, lifestyles, social factors, comorbidities and access to health services, among other valuable information to begin to have a reference source for data and future research.”he expressed Leticia Lopez, Executive Director of APAPPthrough written statements.
The study reportedly addresses questions related to medical history and diagnosis, health coverage, treatment and management of the disease, impact on quality of life, access to medical care and education for psoriasis, risk factors and comorbidities.
“We are confident that with these findings we can raise awareness about psoriasis and provide more data on a disease that significantly affects the lives of many Puerto Ricans. This will contribute to public policy efforts to ensure a better quality of life for psoriasis patients,” said the executive director.
People interested in participating in the study must access this linkIn its first phase, the link will be available until September 30, 2024. Participation is voluntary and all data will be handled with strict confidentiality and through the use of platforms certified by federal laws to conduct this type of study. The exploratory study was designed by Jorge E. Diaz Quinones, biostatistician, and statistics professor Julio Rodriguez Torres.
“We encourage all residents of Puerto Rico who suffer from psoriasis to participate in this study. We are confident that the results of this study will help us to demonstrate the challenges of this disease and will be shared with local and international health authorities,” Lopez emphasized.
What is psoriasis?
Psoriasis is a chronic, systemic, non-communicable inflammatory disease with manifestations in the fur which causes lesions of different sizes to appear. These lesions appear mainly on the elbows, knees and scalp, red and covered with white scales that may disappear and reappear in the same or different parts of the body.
Psoriasis affects approximately 2% of the world’s population. According to the World Health Organization (WHO)this disease is considered a serious, non-contagious and debilitating disease in most cases. Patients with psoriasis have a higher probability of suffering from obesity, intestinal inflammation, cardiovascular diseases and metabolic syndrome compared to the general population.
Suffering from a skin disease such as psoriatic disease has a high impact on both the physical appearance and the emotional and social state of those who suffer from it. It can trigger other mental disorders such as depression, bipolar disorder, schizophrenia and dementia.
